brexafemme Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brexafemme, and when can generic versions of Brexafemme launch?
Brexafemme is a drug marketed by Scynexis and is included in one NDA. There are five patents protecting this drug.
This drug has fifty patent family members in twenty-four countries.
The generic ingredient in BREXAFEMME is ibrexafungerp citrate. One supplier is listed for this compound. Additional details are available on the ibrexafungerp citrate profile page.
DrugPatentWatch® Generic Entry Outlook for Brexafemme
Brexafemme will be eligible for patent challenges on June 1, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for brexafemme
International Patents: | 50 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 11 |
Drug Prices: | Drug price information for brexafemme |
What excipients (inactive ingredients) are in brexafemme? | brexafemme excipients list |
DailyMed Link: | brexafemme at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brexafemme
Generic Entry Date for brexafemme*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for brexafemme
Drug Class | Triterpenoid Antifungal |
Mechanism of Action | Glucan Synthase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for brexafemme
US Patents and Regulatory Information for brexafemme
brexafemme is protected by six US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of brexafemme is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting brexafemme
Salts and polymorphs of SCY-078
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Salts and polymorphs of SCY-078
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
Salts and polymorphs of SCY-078
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
Antifungal agents
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
FDA Regulatory Exclusivity protecting brexafemme
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
Exclusivity Expiration: ⤷ Try a Trial
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Try a Trial
International Patents for brexafemme
When does loss-of-exclusivity occur for brexafemme?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Croatia
Patent: 0220544
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 6874
Estimated Expiration: ⤷ Try a Trial
Patent: 1791645
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Patent: 39684
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 47196
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 58721
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 234
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 47711
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 13111
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering brexafemme around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 111093655 | 在酸性PH值下具有经增强活性的抗真菌剂 (ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH) | ⤷ Try a Trial |
Poland | 3661503 | ⤷ Try a Trial | |
Finland | 3661503 | ⤷ Try a Trial | |
South Korea | 20200044823 | 산성 pH에서 증진된 활성을 갖는 항진균제 | ⤷ Try a Trial |
Slovenia | 3661503 | ⤷ Try a Trial | |
European Patent Office | 4039684 | NOUVEAUX SELS ET POLYMORPHES DE SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078) | ⤷ Try a Trial |
European Patent Office | 2326181 | AGENTS ANTIFONGIQUES (ANTIFUNGAL AGENTS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |